We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Sanofi (SNY) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Sanofi (SNY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Sanofi is one of 902 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SNY is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SNY's full-year earnings has moved 3.78% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that SNY has returned about 1% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -1.17% on a year-to-date basis. This means that Sanofi is performing better than its sector in terms of year-to-date returns.
Breaking things down more, SNY is a member of the Large Cap Pharmaceuticals industry, which includes 15 individual companies and currently sits at #99 in the Zacks Industry Rank. Stocks in this group have gained about 1.11% so far this year, so SNY is slightly underperforming its industry this group in terms of year-to-date returns.
SNY will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Sanofi (SNY) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Sanofi (SNY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Sanofi is one of 902 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SNY is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SNY's full-year earnings has moved 3.78% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that SNY has returned about 1% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -1.17% on a year-to-date basis. This means that Sanofi is performing better than its sector in terms of year-to-date returns.
Breaking things down more, SNY is a member of the Large Cap Pharmaceuticals industry, which includes 15 individual companies and currently sits at #99 in the Zacks Industry Rank. Stocks in this group have gained about 1.11% so far this year, so SNY is slightly underperforming its industry this group in terms of year-to-date returns.
SNY will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.